LL

August 31, 2015

OBI Pharma to Unblind its Phase 2/3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer by March 2016

[…]
June 4, 2015

Clarification about the Progressive Disease (PD) number of the OPT-822-001 Clinical Trial as reported in the Taiwan Media on 4 June 2015

[…]
December 8, 2014

Cancer Active Immunotherapy OBI-822 Mechanelism Action

December 8, 2014

Introduction of OBI PHARMA, INC.’s

[…]